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INTRODUCTION
Most breast cancer-related deaths are caused by distant metastasis of cancer cells rather than local complications of the primary tumors and a significant number of breast cancer eventually experience distant relapse despite the recent improvement of breast cancer treatment. [1] [2] [3] In a prospective trial involving stage I and II early breast cancer patients, the cumulative rate of distant metastasis was 44.0% after 22 years follow-up. [4] The treatment options for patients who develop distant metastasis vary from traditional palliative therapies to more intensive multidisciplinary approaches aiming for potential long-term remissions. [5] A reliable prediction of the expected survival in breast cancer patients with distant metastasis is a critical basis for appropriate treatment selection. Furthermore, for patients with stage IV disease, more than 90% of patients consider the information on survival as the most required information for informed decision making, [6] and sharing detailed information on the expected survival with the patients can help them planning their remaining time. [7] However, accurate prediction of survival in a newly diagnosed metastatic breast cancer patient is one of the most difficult challenges that physicians face.
Several studies have addressed the prognostic factors that determine the overall survival in metastatic breast cancer patients, and found some common clinical factors associated with improved survival such as hormone receptor status and burdens of metastasis. [8] [9] [10] [11] [12] [13] [14] However, at present, we do not have a valid model to identify a potential long-term survivor among the metastatic breast cancer patients.
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In the present study, we aimed to develop a model that predicts the survival after distant metastasis in breast cancer patients.
PATIENTS AND METHODS
To develop a prediction model, the data of patients who underwent curative surgery in Seoul National University Hospital were obtained from the web-based database of Seoul National University Hospital Breast Care Center. [15] Written informed consents were taken prior to surgery in all patients to register their information in the database (IRB No 1405-088-580). The review and analysis of the collected information were separately approved (IRB No. 1308-051-512). All procedures were done in accordance with the Declaration of Helsinki.
We selected patients who were initially diagnosed between Jan 1997 and Dec 2010 and underwent for curative surgery. From the database, we obtained the baseline demographic and clinicopathologic information including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2) status, and Ki-67 expression levels. Initial breast cancer was pathologically staged according to 7th AJCC criteria. We reviewed the electric medical records of the patients to identify the occurrence of distant metastasis and the nature of the metastasis. Patients were excluded if they had suspicious radiologic findings of distant metastasis at the time of initial diagnosis. Distant metastasis did not include the cases with isolated ipsilateral or contralateral breast recurrence, isolated regional lymph node patients, or local chest wall recurrence. Patients who had metachronous carcinoma at other organs, male breast cancer patients, and patients who received prior systemic chemotherapy were excluded from the analysis. The metastatic sites were classified as bone, brain, liver, lung/pleura, distant lymph nodes and multiple site metastases. In instances where patients developed another distant organ involvement within less than 3 months after initial metastasis, they were also considered as multiple site metastases. We investigated the presence of metastasis-related symptoms at the time of first metastasis development based on the each patient's medical record. Ambiguous symptoms such as general weakness or fatigue were not considered as metastasis-related symptoms.
Distant metastasis-free interval was defined as the time from the curative surgery of primary breast cancer to the date of the first distant metastases. Post-metastasis overall survival was measured from first metastasis to the date of death from any cause or to most recent follow-up date. The information of death date was obtained from the Korean National Statistical Office.
To validate the developed prediction model, we obtained pooled clinical data of 254 breast cancer patients from four teaching hospitals in Korea (175 patients from National Cancer Center, 31 patients from Gyeongsang National University Hospital, 24 patients from Dankook University Hospital, and 24 patients from Seoul National University Bundang Hospital). Same exclusion criteria were used for patient selection in the validation set. For Ki-67 expression, patients were classified according to the each institution's median Ki-67 value to adjust the inter-laboratory variations of Ki-67 staining. [16] Survival outcome was estimated by the Kaplan-Meier method and compared across groups using the log-rank. For analyses in where the early events and late events showed different patterns, we added the Gehan-Breslow-Wilcoxon test to stress the importance of early events. For multivariate analysis, a Cox proportional hazards ratio model was used to estimate the adjusted hazard ratio for significance.
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All analyses were carried out using SPSS (version 19.0; SPSS Inc). The statistical significance was assumed at p < 0.05.
RESULTS

Factors affecting survival after distant metastasis
To identify the prognostic factors affecting post-metastasis overall survival, we 
Interaction between the initial tumor stages and the duration of the distant metastasis-free intervals
We analyzed the effect of the initial tumor stages on the post-metastasis overall survival according to the duration of the distant metastasis-free intervals. In patients who developed distant metastasis within 3 years from the initial treatment, the initial tumor stages showed significant association with the post-metastasis overall survival (Figure 2a) . However, in patients who developed distant metastasis after 3 years, the initial tumor stages showed no prognostic significance (Figure 2b ). This observation was in contrast with other prognostic characteristics of the initial tumors such as hormone receptor status or Ki-67 levels, which showed consistent effect regardless of the distant metastasis-free intervals.
Prediction of long-term survivors with distant metastasis
Cox proportional regression model showed initial tumor characteristics such as advanced tumor stage, hormone receptor negativity, high Ki-67 level, and clinical features of metastasis presentation including short duration of disease-free interval, the site of metastasis, and the presence of symptom were independent predictors of shorter survival after distant metastasis (Supplementary Table 1 ). Based on the 9 hazard ratio, we constructed a scoring system, the post-metastasis overall survival score (PMOS Score), to estimate the likelihood of long-term survival in breast cancer patients who developed distant metastasis (Figure 3a) . The PMOS score ranged from 0 to 8, and the patients were categorized into 4 groups according to their scores.
The PMOS score in patients with distant metastasis clearly separated groups of different survival outcomes (p<0.0001). The patients with score 4-5 or score 6-8
showed substantially short post-metastasis survival. The median survival for Group I patients was 71 months while it was 12 months for the Group IV patients (Figure 3b ).
Multicenter validation of the PMOS score
To validate the clinical usefulness of the PMOS score, we constructed an independent dataset of 254 breast cancer patients who developed distant metastasis after initial treatment from four teaching hospitals in Korea. As shown in the Figure   3c , the PMOS score successfully predicted the post-metastasis survival in the validation dataset. Although the survival difference between Group I and Group II was not significant in the validation dataset, the Group III and IV patients showed significantly worse post-metastasis survival (p<0.0001). The median survival for the Group III and IV in the validation dataset was highly reproducible with the value of However, in many patients, the appearance of the first metastasis is often followed by rapid progression in multiple organs making the intensive approach a futile one. [18] Therefore, a valid prediction tool to identify long-term survivors among the metastatic breast cancer patients can offer a reasonable basis of selecting patients for appropriate therapy without increasing unnecessary compromise in quality of life.
Our results show that both initial tumor characteristics and the clinical features of metastasis presentation are significantly associated with the post-metastasis overall survival. Some of the factors were also suggested to be prognostic in previous studies dealing with the outcomes of metastatic breast cancer patients. [8, 10, 11, 13, 19] Based on the findings, we constructed a prediction model to identify long-term survivors after distant metastasis, and validated the clinical usefulness of our prediction model in an independent validation dataset. In both dataset, the group of patients who were predicted to have relatively worse outcome (Group III and IV)
showed median survival of less than 30 months. Based on our model, we propose that these patients are unlikely to benefit from intensive multidisciplinary therapy Our study carries several limitations. First, the retrospective nature of the study necessitates the prospective validation of the prediction model. Second, the classification of the Ki67 staining for the patients included in the multicenter validation dataset was not determined by the absolute value. Rather, we used each institution's median value to define the high Ki67 values due to the apparent interlaboratory variation of the Ki67 staining [16] . Finally, we were not able to collect data on the molecular profiling of the metastastic lesions that may provide a mechanistic insight into the outcomes of the metastatic breast cancer patients [29] . In conclusion, we revealed important prognostic factors in breast cancer patients who developed distant metastasis and elucidated the dynamic interactions between the factors. Based on our observations, we have constructed a prediction model that can help patients to obtain more clear insights into their future outcomes and can also guide the physicians to select personalized treatment options for individual metastatic breast cancer patients. 
